Terns Pharmaceuticals Welcomes New Talent with Equity Grant
Terns Pharmaceuticals, Inc., a pioneering biopharmaceutical company, has taken significant steps to strengthen its team by granting an equity inducement award to a new employee as of February 1. This decision aligns with Terns’ goal of attracting and retaining top talent in the clinical stage of drug development, particularly in the fields of oncology and obesity.
The Inducement Grant Details
The award, facilitated under the 2022 Employment Inducement Award Plan, was approved by the Compensation Committee of Terns' Board of Directors. This strategic move was aimed at providing a substantial incentive for the new employee's acceptance of their position at Terns Pharmaceuticals. The company has granted options to purchase 250,000 shares of its common stock, a gesture that underscores Terns' commitment to fostering an engaging and rewarding work environment.
Vesting and Terms of the Options
The options come with a 10-year term, and the exercise price has been set at $4.46 per share. This amount corresponds to the closing price of Terns’ common stock on the last trading day prior to the grant. Notably, these options will vest over a four-year period, contingent upon the employee's continued service, ensuring a long-term commitment to the company.
About Terns Pharmaceuticals
Terns Pharmaceuticals is at the forefront of developing innovative small-molecule product candidates targeting severe diseases. With a dynamic pipeline featuring three clinical-stage development programs, the company is focused on creating viable therapies that include an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-? agonist. Terns is also actively exploring newer avenues, including a preclinical GIPR modulator discovery effort aimed at prioritizing a GIPR antagonist nomination candidate.
Innovation and Growth Objectives
As Terns Pharmaceuticals continues to evolve, its commitment to research and innovation remains steadfast. By strategically enhancing its workforce, Terns is positioning itself to make significant strides in clinical stages and beyond, paving the way for breakthroughs in treatment options for serious conditions. The company's investment in its employees is integral to fostering an environment conducive to success.
Contact Information for Terns Pharmaceuticals
For inquiries related to investments, Justin Ng represents the investor relations team, providing insights and assistance to potential and current investors. You can reach him through the official Terns Pharmaceuticals contact for investors.
Media Inquiries
Jenna Urban is the primary contact for media relations at Terns Pharmaceuticals, ensuring that all communications regarding the company's activities are effectively managed and disseminated.
Frequently Asked Questions
What is the purpose of the equity inducement grant?
The equity inducement grant is designed to attract and retain top talent by providing substantial financial incentives through stock options.
How many shares were granted to the new employee?
The new employee was granted options to purchase 250,000 shares of Terns common stock.
What is the duration of the options granted?
The options granted have a duration of 10 years.
What conditions must be met for the options to vest?
The options vest over four years, subject to the employee’s continued service at the company.
What is Terns Pharmaceuticals' focus in drug development?
Terns Pharmaceuticals focuses on developing small-molecule product candidates to treat severe diseases, including oncology and obesity.
